Complimentary white paper to help marketers stay ahead of the digital marketing curve

Manhattan ResearchThe new year was ushered in amidst economic uncertainties and the impending inauguration of a new administration - the effects of which have great implications for the pharmaceutical industry. Brand managers especially will feel the heat as marketing spend and measurement is increasingly scrutinized. But despite the doom and gloom in predictions for the year ahead, physicians and patients will continue to use healthcare products and services and companies still need to find ways to effectively reach their target audiences.

Pharmaceutical and healthcare market research company Manhattan Research releases a complimentary white paper outlining the top New Year's resolutions for marketers looking to take advantage of the latest eHealth trends to better target physician and consumer groups and push their brand ahead on the digital marketing curve.

Top Five Pharma Brand Manager Resolutions:
1. Don't Forget About Search
2. Reassess Your Customer Service Model
3. Keep an Eye on Mobile
4. Think Outside of the Bag - A New Look at the Traditional Sales Force Model
5. Measure…and Keep Measuring!

Download the Full White Paper
"Pharma Brand Manager New Year’s Resolutions: Five Strategies for Staying Ahead in 2009" expands upon the above resolutions and reveals the latest eHealth tips and trends for improving brand strategies and connections with consumer and physician audiences. To access the full white paper, please visit: http://www.manhattanresearch.com/research/white-papers/
pharma-brand-manager-resolutions.aspx

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, ePharma Physician®, Cybercitizen Health™, Cybercitizen Health™ Europe, and ePharma Consumer®. Broad consumer and physician research is complemented by targeted analysis among more than 100 consumer therapeutic segments and 25 physician specialist segments.

For information, please visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

Most Popular Now

Pfizer announces positive top-line results from Ph…

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Enzyme that protects against viruses could fuel ca…

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a ...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...